Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') announced the successful inclusion of all five of the Company's self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL ...
Woman's World on MSN
Ozempic 2.0! Experts call GLP-1 pills a game-changer for weight loss—here's how they work and when to expect them
Imagine if losing weight were as simple as swallowing a daily pill-no needles, no injections and no anxiety. If you're among ...
Gastric Cancer Diagnostics Market size was valued at US$ 3.5 Bn in 2024 and is projected to reach US$ 6.9 Bn by 2035, growing ...
Leading Edge Health's GenuinePurity brand addresses authentication challenges and bioavailability concerns with certificate ...
In conjunction with Tract’s move to Connect Labs Charlotte, the company’s scientific co-founders, Frank McKeon, Ph.D., and Wa ...
A research team from the LKS Faculty of Medicine at the University of Hong Kong (HKUMed) has made a breakthrough in gastric ...
Department of General Surgery, The First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China Background: Gastric cancer (GC) is a leading gastrointestinal malignancy ...
1 Child Healthcare Department, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China 2 Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, ...
Gastric cancer often develops through a gradual sequence of changes, beginning with superficial gastritis and advancing through chronic atrophic gastritis, intestinal metaplasia, and precancerous ...
6 Key Laboratory of Research on Clinical Molecular Diagnosis for High Incidence Diseases in Western Guangxi, Guangxi, Guangxi, People's Republic of China Background Gastrointestinal cancers comprise ...
KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback